Human Peptide Hormone
Active Substance: Tirzepatide
Manufacturer: Kalpa Pharmaceuticals
Unit: 2 mL Vial (5 mg/vial)
Mounjarixyl is also known in the market as Tirzepatide.
Mounjarixyl, developed by Kalpa Pharmaceuticals, is an innovative medication that comes in a powder form, designed to be reconstituted and administered as an injectable solution. It contains the active substance Tirzepatide, which is a breakthrough in metabolic disease management, particularly diabetes.
Each vial of Mounjarixyl contains 5 mg of Tirzepatide in a 2 mL vial, providing a precise dosage aimed at therapeutic efficacy with controlled administration.
While primarily not a bodybuilding drug, Mounjarixyl has potential benefits in a bodybuilding context due to its effects on body composition. It can aid in fat loss and improve glucose metabolism, which might be beneficial during cutting phases to maintain a lean physique.
Mounjarixyl is indicated for the treatment of type 2 diabetes as it enhances both the incretin hormone GLP-1 and GIP, leading to improved blood sugar levels and reduced appetite. It is significant for patients who are also looking to manage their weight as part of their diabetes treatment plan.
For therapeutic purposes, the typical dosage starts at a small dose to assess tolerance and is gradually increased based on the treatment protocol and medical guidance.
Similar to men, the dosage for women starts low and is adjusted according to the therapeutic needs and responses monitored by healthcare providers.
The active life of Tirzepatide in the body spans several days, allowing for less frequent dosing compared to other diabetes medications, usually once weekly.
Potential side effects of Mounjarixyl include gastrointestinal symptoms such as nausea, vomiting, diarrhea, and a potential risk of hypoglycemia when combined with other diabetes medications. Users may also experience injection site reactions.
Mounjarixyl is contraindicated in patients with a personal or family history of medullary thyroid carcinoma and in those with Multiple Endocrine Neoplasia syndrome type 2. Patients with severe gastrointestinal disease should also use it cautiously.
An overdose of Mounjarixyl may result in severe nausea, vomiting, and hypoglycemic reactions. Immediate medical attention is required in cases of suspected overdose.
In a therapeutic setting, Mounjarixyl might be used in conjunction with other diabetes medications such as Metformin or SGLT2 inhibitors to enhance glycemic control. For bodybuilders, stacking is not applicable as its primary use is not performance enhancement.
Mounjarixyl is presented in 2 mL vials containing 5 mg of Tirzepatide as a lyophilized powder for reconstitution.
Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Keep the vial away from light and moisture. After reconstitution, use it within the prescribed time as advised by health care professionals.
Mounjarixyl by Kalpa Pharmaceuticals represents a significant advancement in the treatment of type 2 diabetes with benefits that extend into weight management. It's crucial for users to follow their healthcare provider's instructions and to monitor their health regularly while on this medication.
Human Peptide Hormone
Active Substance: Tirzepatide
Manufacturer: Dragon Pharma
Unit: 2 mL Vial (5 mg/vial) Form: Powder
Human Peptide Hormone
Active Substance: Tirzepatide
Manufacturer: Ordinary Steroids USA
Unit: 2 mL Vial (20 mg/vial)
Human Peptide Hormone
Active Substance: Tirzepatide
Manufacturer: Beligas Pharmaceuticals
Unit: 2 mL Vial (10 mg/vial)
Human Peptide Hormone
Active Substance: Tirzepatide
Manufacturer: Xeno Laboratories
Unit: 2 mL Vial (5 mg/vial)